A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
Active, not recruiting · Phase 1, Phase 2 · NCT05095727
Conditions: Glycogen Storage Disease
At a glance
- Research payments reported, 2025
- $415,683
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-3745 (drug)
- Dates
- Started 2022-06-01; completion 2026-11-30
- Results posted
- Not yet
The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.
From ClinicalTrials.gov, last updated 2025-12-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $415,683 in research payments for this study in 2025 (86 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Karen Loechner, MD, PHD Pediatric Endocrinology · Farmington, CT
- Brian Shayota, M.D., M.P.H. Medical Genetics · Oklahoma City, OK
- Diva D. Deleon, M.D. Pediatric Endocrinology · Philadelphia, PA
- Laura S. Farach, M.D. Medical Genetics · Houston, TX
- Kevin E. Glinton, M.D. Medical Genetics · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Utah Hospital and Clinics, UT $115,995
- University of Connecticut Health Center $97,111
- Baylor College of Medicine $91,200
- Duke University $87,259
- Children's Hospital of Philadelphia, PA $13,369
- The University of Texas Health $10,749
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.